Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Common Equity: 2019-2025

Historic Common Equity for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $946.3 million.

  • Kymera Therapeutics' Common Equity rose 5.97% to $946.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.3 million, marking a year-over-year increase of 5.97%. This contributed to the annual value of $835.6 million for FY2024, which is 111.56% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Common Equity is $946.3 million, which was down 2.60% from $971.5 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Common Equity high stood at $971.5 million for Q2 2025, and its period low was $258.1 million during Q2 2021.
  • Moreover, its 3-year median value for Common Equity was $711.2 million (2024), whereas its average is $683.3 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Common Equity spiked by 393.43% in 2021, and later fell by 22.88% in 2023.
  • Kymera Therapeutics' Common Equity (Quarterly) stood at $459.6 million in 2021, then climbed by 6.64% to $490.2 million in 2022, then dropped by 19.42% to $395.0 million in 2023, then skyrocketed by 111.56% to $835.6 million in 2024, then grew by 5.97% to $946.3 million in 2025.
  • Its Common Equity was $946.3 million in Q3 2025, compared to $971.5 million in Q2 2025 and $786.2 million in Q1 2025.